Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.735 USD | -8.23% | -14.73% | +84.90% |
Financials (USD)
Sales 2024 * | 50.21M | Sales 2025 * | 57.98M | Capitalization | 371M |
---|---|---|---|---|---|
Net income 2024 * | -27M | Net income 2025 * | -27M | EV / Sales 2024 * | 6.98 x |
Net cash position 2024 * | 20.23M | Net Debt 2025 * | 15.47M | EV / Sales 2025 * | 6.66 x |
P/E ratio 2024 * |
-11.4
x | P/E ratio 2025 * |
-13.8
x | Employees | 135 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95% |
Latest transcript on Aquestive Therapeutics, Inc.
1 day | -8.23% | ||
1 week | -12.73% | ||
Current month | -12.32% | ||
1 month | -9.56% | ||
3 months | +56.93% | ||
6 months | +147.35% | ||
Current year | +84.90% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Barber
CEO | Chief Executive Officer | 48 | 07-06-30 |
A. Toth
DFI | Director of Finance/CFO | 65 | 20-12-30 |
Stephen Wargacki
CTO | Chief Tech/Sci/R&D Officer | 46 | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 22-08-09 |
Santo Costa
CHM | Chairman | 78 | 15-11-30 |
Gregory Brown
BRD | Director/Board Member | 70 | 07-02-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 3.735 | -8.23% | 7,632,648 |
24-04-26 | 4.07 | +3.56% | 2,986,647 |
24-04-25 | 3.93 | +0.77% | 1,935,903 |
24-04-24 | 3.9 | -8.88% | 2,147,676 |
24-04-23 | 4.28 | -2.28% | 1,699,537 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+84.90% | 371M | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- AQST Stock